ADMA vs. NMRA, TARS, FDMT, INBX, FUSN, VIR, BEAM, CGEM, SRRK, and DNA
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Neumora Therapeutics (NMRA), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), Inhibrx (INBX), Fusion Pharmaceuticals (FUSN), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Cullinan Oncology (CGEM), Scholar Rock (SRRK), and Ginkgo Bioworks (DNA). These companies are all part of the "biological products, except diagnostic" industry.
ADMA Biologics (NASDAQ:ADMA) and Neumora Therapeutics (NASDAQ:NMRA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
Neumora Therapeutics has a net margin of 0.00% compared to ADMA Biologics' net margin of -1.29%. ADMA Biologics' return on equity of 17.24% beat Neumora Therapeutics' return on equity.
In the previous week, ADMA Biologics had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 4 mentions for ADMA Biologics and 1 mentions for Neumora Therapeutics. ADMA Biologics' average media sentiment score of 0.27 beat Neumora Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media.
ADMA Biologics has higher revenue and earnings than Neumora Therapeutics.
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ADMA Biologics currently has a consensus price target of $10.50, indicating a potential upside of 12.78%. Neumora Therapeutics has a consensus price target of $22.57, indicating a potential upside of 138.60%. Given Neumora Therapeutics' higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than ADMA Biologics.
ADMA Biologics received 395 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 71.68% of users gave ADMA Biologics an outperform vote.
Summary
ADMA Biologics beats Neumora Therapeutics on 11 of the 15 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
